Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 15;9(11):5127-5137.
eCollection 2017.

Downregulation of cathepsin G reduces the activation of CD4+ T cells in murine autoimmune diabetes

Fang Zou  1 , Xiaoyang Lai  1 , Jing Li  1 , Shuihong Lei  1 , Lei Hu  1
Affiliations

Downregulation of cathepsin G reduces the activation of CD4+ T cells in murine autoimmune diabetes

Fang Zou et al. Am J Transl Res. .

Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune disease due to progressive injury of islet cells mediated by T lymphocytes (T cells). Our previous studies have shown that only cathepsin G (CatG), not other proteases, is involved in the antigen presentation of proinsulin, and if the presentation is inhibited, the activation of CD4+ T cells induced by proinsulin is alleviated in T1DM patients, and CatG-specific inhibitor reduces the activation of CD4+ cells induced by proinsulin in T1DM patients. Therefore, we hypothesize that CatG may play an important role in the activation of CD4+ T cells in T1DM. To this end, mouse studies were conducted to demonstrate that CatG impacts the activation of CD4+ T cells in non-obese diabetic (NOD) mice. CatG gene expression and the activation of CD4+ T cells were examined in NOD mice. The effect of CatG inhibitor was investigated in NOD mice on the activation of CD4+ T cells, islet β cell function, islet inflammation and β-cell apoptosis. Furthermore, NOD mice were injected with CatG siRNA in early stage to observe the effect of CatG knockdown on the activation status of CD4+ T cells and the progression of diabetes. During the pathogenesis of diabetes, the expression level of CatG in NOD mice gradually increased and the CD4+ T cells were gradually activated, resulting in more TH1 cells and less TH2 and Treg cells. Treatment with CatG-specific inhibitor reduced the blood glucose level, improved the function of islet β cells and reduced the activation of CD4+ T cells. Early application of CatG siRNA improved the function of islet β cells, reduced islet inflammation and β cell apoptosis, and lowered the activation level of CD4+ T cells, thus slowing down the progression of diabetes.

Keywords: CD4+ T cells; NOD mice; cathepsin G; type 1 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Gene expression of CatG and the activation of CD4+ T cells in NOD mice. A. mRNA level of CatG; B. Upper panel: cytometry assay of T cells, lower panel: percentage of CD4+ T subsets. ** and *** denote P < 0.01 and 0.001 vs normal.
Figure 2
Figure 2
Effect of cathepsin G inhibitor on blood glucose, insulin levle and islet β cell apoptosis in NOD mice. A. Blood glucose level over time; B. Serum insulin level over time, C. Islet H&E staining; D. Flow cytometry assay of apoptotic cells and apoptotic rate. ** Denotes P < 0.01 vs control.
Figure 3
Figure 3
Effect of cathepsin G inhibitor on the activation of CD4+ T cells in NOD mice. A. Cytometry assay of T cells and percentage of CD4+ T subsets in spleen and peripheral blood; B. mRNA level of CatG. **P < 0.01 vs control.
Figure 4
Figure 4
Effect of CatG siRNA on the blood glucose, insulin levels and β cell apoptosis in NOD mice. A. Relative GatG mRNA level; B and C. Blood glucose and insulin levels over time; D. Islet H&E staining; E. Flow cytometry assay and percentage of apoptosis. ** Denotes P < 0.01 vs control.
Figure 5
Figure 5
Effect of CatG siRNA treatment on the activation of CD4+ T cells in pre-DM NOD mice. Upper panel: cytometry assay of T cells, lower panel: percentage of CD4+ T subsets in spleen and peripheral blood. ** Denotes P < 0.01 vs control.
See this image and copyright information in PMC

References

    1. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986;314:1360–1368. - PubMed
    1. Roep BO, Tree TI. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol. 2014;10:229–242. - PubMed
    1. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol. 2013;9:92–103. - PubMed
    1. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS Type 1 Diabetes TrialNet Canakinumab Study Group; Pickersgill L, de Koning E, Ziegler AG, Boehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381:1905–1915. - PMC - PubMed
    1. Ludvigsson J, Krisky D, Casas R, Battelino T, Castano L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J, Samuelsson U, Elding Larsson H, Aman J, Kardell G, Neiderud Helsingborg J, Lundstrom G, Albinsson E, Carlsson A, Nordvall M, Fors H, Arvidsson CG, Edvardson S, Hanas R, Larsson K, Rathsman B, Forsgren H, Desaix H, Forsander G, Nilsson NO, Akesson CG, Keskinen P, Veijola R, Talvitie T, Raile K, Kapellen T, Burger W, Neu A, Engelsberger I, Heidtmann B, Bechtold S, Leslie D, Chiarelli F, Cicognani A, Chiumello G, Cerutti F, Zuccotti GV, Gomez Gila A, Rica I, Barrio R, Clemente M, Lopez Garcia MJ, Rodriguez M, Gonzalez I, Lopez JP, Oyarzabal M, Reeser HM, Nuboer R, Stouthart P, Bratina N, Bratanic N, de Kerdanet M, Weill J, Ser N, Barat P, Bertrand AM, Carel JC, Reynaud R, Coutant R, Baron S. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012;366:433–442. - PubMed

LinkOut - more resources